AEON · AEON BIOPHARMA INC
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Market Cap
10.06M
52 Wk Range
$0.13 - $1.45
Previous Close
$0.14
Open
$0.16
Volume
4,348,801
Day Range
$0.16 - $0.16
Enterprise Value
9.406M
Cash
3.431M
Avg Qtr Burn
-3.698M
Insider Ownership
54.32%
Institutional Own.
23.71%
Qtr Updated
Jun 30th 2026
